secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011465
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q2 net loss $0.60/shr; cash $190.5M; Phase 3 SAPPHIRE data on track Q4 2024
--------------------------------------------------------------------------------

- Net loss $58.5M ($0.60/shr) vs $37.9M ($0.47/shr) in Q2 2023; no revenue.
- Cash $190.5M; expected to fund operations into H2 2025.
- Phase 3 SAPPHIRE topline data for apitegromab in SMA expected Q4 2024; commercial launch targeted 2025 if successful.
- Phase 2 EMBRAZE (apitegromab + GLP-1 in obesity) now expects topline data Q2 2025; IND for SRK-439 planned in 2025.
- Long-term TOPAZ data: 48-month mean HFMSE improvement 5.3 points (2-21 yrs); >90% patient retention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/0001558370-24-011465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/srrk-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer